Bifunctional BTK Degrader with E3 Ligase Linker
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inhibiting Bruton's tyrosine kinase (BTK) are not sufficient to effectively treat diseases such as cancer and autoimmune disorders, as they may not provide the necessary potency or temporal control over protein expression.
Innovation Solution
Development of novel bifunctional compounds that recruit targeted proteins, such as BTK, to E3 ubiquitin ligases for degradation, utilizing a targeting ligand, a linker, and a degron moiety to facilitate proteasome-mediated degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional BTK inhibitors are used, then BTK activity is inhibited, but the potency and temporal control over protein expression are insufficient
Solution Approach 1:
The bifunctional compound is divided into two distinct functional segments: a BTK-binding moiety (such as a BTK inhibitor fragment) and an E3 ligase-binding moiety (degron). This segmentation allows each segment to independently perform its specific function - binding to BTK and binding to the E3 ligase respectively - thereby achieving both high inhibition potency and temporal control over protein expression through proteasome-mediated degradation.
Solution Approach 2:
The patent merges two previously separate functions into a single bifunctional compound: (1) BTK inhibition through the BTK-binding moiety, and (2) proteasome-mediated degradation through the E3 ligase-binding moiety. This combining allows the compound to simultaneously achieve potent BTK inhibition and temporal control over protein expression levels, resolving the contradiction between these two requirements.
2Reliability
If conventional BTK inhibitors are used, then BTK signaling is blocked, but therapeutic efficacy is limited
Solution Approach 1:
The patent converts the natural degradation pathway of BTK (which requires E3 ligase recognition) into a therapeutic benefit by designing a bifunctional compound that exploits this pathway. Instead of merely blocking BTK activity as conventional inhibitors do, the compound promotes BTK degradation through the E3 ligase-binding moiety, turning the degradation mechanism into a beneficial therapeutic effect that enhances efficacy and reduces resistance.
Solution Approach 2:
The patent changes the mechanism of action parameter from direct BTK activity inhibition to promotion of BTK protein degradation. By altering the fundamental approach from blocking signaling to removing the protein entirely, the therapeutic efficacy is enhanced and the potential for resistance development is reduced, as degradation provides a more complete and sustained suppression of BTK function.
3Reliability
If bifunctional compounds are designed, then specific and potent BTK inhibition is achieved, but compound complexity increases
Solution Approach 1:
The bifunctional compound design embodies multi-functionality by incorporating both a BTK-binding moiety and an E3 ligase-binding moiety within a single molecular structure. This universal approach allows the compound to perform multiple functions - inhibiting BTK activity and promoting its degradation - thereby achieving specific and potent inhibition while managing the complexity through a unified molecular design rather than multiple separate agents.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bifunctional compounds achieve specific and potent inhibition of BTK by promoting its degradation, potentially offering improved therapeutic efficacy compared to existing inhibitors and providing a novel mechanism of action for treating various diseases.
Implementation Method 1
The bifunctional compound comprises a targeting ligand capable of binding to BTK, a linker that covalently binds the targeting ligand and the degron, and a degron capable of binding to cereblon
Implementation Method 2
The covalent attachment of ubiquitin to specific protein substrates is achieved through the action of E3 ubiquitin ligases. These ligases comprise over 500 different proteins and are categorized into multiple classes defined by the structural element of their E3 functional activity.
Data Source
AI summary
The present application provides bifunctional compounds of Formula (X):or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for Bruton's tyrosine kinase (BTK). The present application also relates to methods for the targeted degradation of BTK through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to BTK which can be utilized in the treatment of disorders modulated by BTK.